A5074584421- Phosphodiesterase function and regulation
- Cancer-related molecular mechanisms research
- Receptor Mechanisms and Signaling
- Histone Deacetylase Inhibitors Research
- RNA Research and Splicing
- Ferroptosis and cancer prognosis
- Molecular Biology Techniques and Applications
- Circular RNAs in diseases
Bilkent University
2018-2025
Beykent University
2023-2025
Abstract Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER + ) breast cancer, constituting around 75% of all cases. However, emergence resistance is common, necessitating identification novel therapeutic targets. Here, we demonstrated that long-noncoding RNA LINC00152 confers tamoxifen by blocking tamoxifen-induced ferroptosis, an iron-mediated cell death. Mechanistically, inhibiting reduces mRNA stability...
Abstract Purpose: Tamoxifen remains an important hormonal therapy for ER-positive breast cancer; however, development of resistance is a major obstacle in clinics. Here, we aimed to identify novel mechanisms tamoxifen and provide actionable drug targets overcoming resistance. Experimental Design: Whole-transcriptome sequencing, downstream pathway analysis, repositioning approaches were used modulators [here: phosphodiesterase 4D (PDE4D)] Clinical data involving tamoxifen-treated patients...
Abstract Phosphodiesterase 4D (PDE4D) is a member of the phosphodiesterase family enzymes, catalyzing hydrolysis cAMP second messenger and inhibiting signaling. Targeting PDE4D raises intracellular levels, leading to apoptosis cell cycle arrest in different tumor types. However, its contribution drug resistance metastasis still elusive. lncRNAs are more than 200 nucleotides length carry out diverse functions including transcriptional regulation, regulation proteins or RNA molecules by direct...
Abstract Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER+) breast cancer, constituting around 75% of all cases. However, emergence resistance is common, necessitating identification novel therapeutic targets. Here, we demonstrated that long-noncoding RNA LINC00152 confers tamoxifen via blocking tamoxifen-induced ferroptosis, an iron-mediated cell death. Mechanistically, inhibiting reduces mRNA stability phosphodiesterase...
<p>This file contains supplementary methods, 7 figures and 5 tables.</p>
<p>Mishra and Sahin patent info for Conflict of Interest</p>
<div>Abstract<p><b>Purpose:</b> Tamoxifen remains an important hormonal therapy for ER-positive breast cancer; however, development of resistance is a major obstacle in clinics. Here, we aimed to identify novel mechanisms tamoxifen and provide actionable drug targets overcoming resistance.</p><p><b>Experimental Design:</b> Whole-transcriptome sequencing, downstream pathway analysis, repositioning approaches were used modulators [here:...
<div>Abstract<p><b>Purpose:</b> Tamoxifen remains an important hormonal therapy for ER-positive breast cancer; however, development of resistance is a major obstacle in clinics. Here, we aimed to identify novel mechanisms tamoxifen and provide actionable drug targets overcoming resistance.</p><p><b>Experimental Design:</b> Whole-transcriptome sequencing, downstream pathway analysis, repositioning approaches were used modulators [here:...
<p>Mishra and Sahin patent info for Conflict of Interest</p>
<p>This file contains supplementary methods, 7 figures and 5 tables.</p>
Abstract Estrogen receptor (ER) positive breast cancer accounts for about 75% of all cases. Tamoxifen has been the mainstay therapy over 40 years that is used to treat early, locally advanced, and metastatic ER-positive cancers. Despite initial clinical success, approximately 20-30% high-risk, advanced patients are resistant tamoxifen or develop resistance time which significantly decreases survival. Long-noncoding RNAs (lncRNAs) a class non-coding more than 200 nucleotides in length...